Studies heart attack patients to find markers of future heart outcomes
Follows adults with ST-elevation heart attack using blood samples, imaging and quality-of-life questionnaires.
Plain-language title generated from the registry record
Registry title: Cohort of STEMI Patients 2
Key facts
- Where
- Bron and Lyon, FranceSee the 2 sites
Where in France
- Hospices Civils de Lyon - Hopital Louis PradelBron, FranceTaking people
- Hospices Civils de Lyon - Hôpital de la Croix RousseLyon, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT05794022
- Record updated
- 14 May 2026
- Original description
ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for 75% of sudden deaths in adults over 35 years of age and more than half of all cases of chronic heart failure. However, the mechanism of myocardial infarction remains poorly understood. At present, there is no national information system for myocardial infarction, as there is for other diseases such as multiple sclerosis (OFSEP cohort).Read full original descriptionShow less
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction
ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for 75% of sudden deaths in adults over 35 years of age and more than half of all cases of chronic heart failure. However, the mechanism of myocardial infarction remains poorly understood. At present, there is no national information system for myocardial infarction, as there is for other diseases such as multiple sclerosis (OFSEP cohort).
The purpose of this cohort is to enable studies and research projects to be carried out on the descriptive epidemiology of myocardial infarction, monitoring of patients undergoing treatment (safety, efficacy), quality of life and functional consequences of infarction, and research into new biological and imaging prognostic biomarkers. Its general objective is to provide researchers, hospital practitioners, medical interns, academics or industrialists with a quality epidemiological tool for research.
Inclusion: Age ≥ 18 years; Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG; Management in primary ACT; Prior oral informed consent followed by signed informed consent as soon as possible.
Exclusion: Obvious contraindication to injected magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, or a metallic body (ferromagnetic), severe renal insufficiency (GFR<30 ml/min), known allergy to the contrast medium ....); Pregnant woman or woman of childbearing age without effective contraception, breastfeeding woman; Diagnosis of STEMI not confirmed on angiography; Inability to give the subject informed information; Lack of coverage by a social security scheme; Deprivation of civil rights (curators, guardianship, safeguard of justice).